Related Experiment Video
Updated: May 22, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events
Antonio Abbate1, Benjamin W Van Tassell, Giuseppe G L Biondi-Zoccai
1VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, 23298, USA. aabbate@mcvh-vcu.edu
Abstract:
The inflammatory hypothesis of atherosclerosis postulates that inflammation within the plaque promotes plaque progression and complications. Interleukin-1 (IL-1) is a key pro-inflammatory cytokine responsible for the amplification of the inflammatory response following injury. Animal studies show that IL-1 blockade is effective in limiting atherosclerosis and atherothrombosis and improving outcomes in acute myocardial infarction and ischemic stroke. Preliminary data in patients with acute myocardial infarction, ischemic stroke, and heart failure are promising. A large secondary prevention trial with canakinumab in patients with prior acute myocardial infarction is currently ongoing. Many unanswered questions remain regarding the optimal use of IL-1 blockade and the preferred agent.
Related Concept Videos
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Venous Thrombosis III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Myocarditis III: Medical Management
